Pharvaris N.V. (PHVS) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Vera Therapeutics (VERA) over the past year, gaining 41.2% versus a loss of 1.8%. Over five years, VERA leads with a +101.5% price change compared with +100.5% for PHVS. Pharvaris N.V. is the larger company by market cap ($2.22 billion vs $2.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | VERA |
|---|---|---|
| Share price | $31.68 | $30.25 |
| Market cap | $2.22B | $2.18B |
| 1-day change | +1.80% | +2.82% |
| YTD return | +14.16% | -40.26% |
| 1-year return | +41.18% | -1.79% |
| 5-year return | +100.51% | +101.53% |
| EPS (TTM) | $-3.06 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.25 | $56.05 |
| 52-week low | $20.65 | $23.05 |
| Distance from 52-week high | -26.75% | -46.03% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.62% | +156.20% |
| Average volume | 740.93K | 2.21M |
| Shares outstanding | 70.20M | 72.06M |
| Employees | 148 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed VERA by 43.0 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
PHVS vs VERA FAQ
Which is bigger, Pharvaris N.V. or Vera Therapeutics?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.22B compared with $2.18B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, PHVS or VERA?
PHVS returned +41.18% over the past 12 months, compared with -1.79% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.